Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1A | O00555 | 1/20 | 0.56 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.56 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21035355 | 0.86 | OPRD1 (0.53) | CACNA1ACACNA2D1CACNB1SLC6A9OPRD1 | |
| SCHEMBL21035582 | 0.86 | OPRD1 (0.53) | CACNA1ACACNA2D1CACNB1SLC6A9OPRD1 | |
| SCHEMBL5547616 | 0.81 | CACNA2D1 (0.39) | CACNA1ACACNA2D1CACNB1SLC6A2SLC6A3 | |
| SCHEMBL3292513 | 0.78 | CACNA1A (0.58) | CACNA1ACACNA2D1CACNB1SLC6A9OPRD1 | |
| SCHEMBL21035066 | 0.78 | CACNA2D1 (0.48) | CACNA1ACACNA2D1CACNB1SLC6A9OPRD1 | |
| SCHEMBL7801902 | 0.77 | L3MBTL1 (0.54) | KDM4EALDH1A1 | |
| SCHEMBL7660403 | 0.77 | SIGMAR1 (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2TSHR | |
| SCHEMBL13724968 | 0.77 | SLC6A2 (0.50) | CACNA1ACACNA2D1CACNB1SLC6A2SLC6A3 | |
| SCHEMBL13724540 | 0.77 | SLC6A2 (0.50) | CACNA1ACACNA2D1CACNB1SLC6A2SLC6A3 | |
| SCHEMBL5392078 | 0.77 | ALDH1A1 (0.66) | CACNA1ACACNA2D1CACNB1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610792-B1 | CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES | NEUROMED TECH INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| EP-1610792-B1 | CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES | NEUROMED TECH INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | NEUROMED TECHNOLOGIES INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | NEUROMED TECHNOLOGIES INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | NEUROMED TECHNOLOGIES INC. | 2006-04-20 | — | — | US | disclosed |
| EP-1610792-A1 | CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES | Neuromed Technologies, Inc. (CA) | 2006-01-04 | — | — | EP | disclosed |
| US-6951862-B2 | Calcium channel blockers comprising two benzhydril moieties | NEUROMED TECHNOLOGIES, INC. (CA) | 2005-10-04 | — | — | US | disclosed |
| US-6949554-B2 | Calcium channel blockers comprising two benzhydril moieties | NEUROMED TECHNOLOGIES INC. (CA) | 2005-09-27 | — | — | US | disclosed |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-23 | — | — | US | disclosed |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-23 | — | — | US | disclosed |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-23 | — | — | US | disclosed |
| WO-2004089377-A1 | CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089377-A1 | CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-10-21 | — | — | WO | disclosed |
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-10-21 | — | — | US | disclosed |
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-10-21 | — | — | US | disclosed |
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-10-21 | — | — | US | disclosed |
| US-20040034035-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES, INC. | 2004-02-19 | — | — | US | disclosed |
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | disclosed |
| EP-0068544-B1 | NOVEL N-ARYL-PIPERAZINEALKANAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-06-03 | — | — | EP | disclosed |
| EP-0068544-A2 | Novel N-aryl-piperazinealkanamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | CACNA1A 19/4885CACNA2D1 41/4885CACNB1 14/4885 |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | CACNA1D, CACNA1E, CACNA1B | CACNA1A 10/4885CACNA2D1 21/4885CACNB1 36/4885 |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | CACNA1A 19/4885CACNA2D1 41/4885CACNB1 14/4885 |
| US-20040034035-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | CACNA1A 15/4885CACNA2D1 30/4885CACNB1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.